Clearside Q3 2024 net loss $7.7M; ODYSSEY Phase 2b wet AMD trial hits all endpoints

Clearside Biomedical, Inc.

2024-Q3 EPS reported -$0.37 revenue$1,358,000

Net loss of $7.7M ($0.10 per share) vs. $9.3M ($0.15) in Q3 2023; revenue $1.0M, up from $0.9M.
ODYSSEY Phase 2b of suprachoroidal CLS-AX in wet AMD met all primary and secondary outcomes with extended duration.
Cash, equivalents and short-term investments $23.6M as of Sep 30, 2024; runway into Q3 2025.
Asia-Pacific partner Arctic Vision licensed ARVN001 to Santen for China; Phase 3 UME data positive.
Tony Gibney appointed Chair of Board; REGENXBIO advances ABBV-RGX-314 via SCS Microinjector toward pivotal trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.